PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. These annual results provide valuable insights into the state of drug development, highlighting shifts in industry practices and illuminating emergent areas of focus.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Drug Target Review

JULY 4, 2023

The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. Antibody drug conjugated with cytotoxic payload. antibody linked to a biologically active cytotoxic (anticancer) payload or drug 3d rendering. Cancer Cell [Internet]. 2022 [cited 2023 Feb 10];30(2):71.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

APRIL 6, 2022

. “With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.

International 52

International Pharmaceuticals Drug Development Marketing 52

Alta Sciences

JANUARY 31, 2025

A non-profit organization, STC was founded in 1965 with 15 scientists from Montral-based pharmaceutical companies. It owned the societal name of the Canadian Association for Research on Drug Safety. The STC is an intimate gathering of scientists with a fervor to acquire and apply knowledge in toxicology.

Cell Biology 52

Cell Biology Pharmaceutical Companies Clinical Research Government 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 /PRNewswire/ — At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. Ionis projects having the opportunity to launch six or more new products through 2026, with each being ready for launch in a close window, ranging from 18 to 24 months between each new product launch. About Ionis Pharmaceuticals, Inc.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

Agency IQ

AUGUST 2, 2024

While this would not affect existing vouchers, it would prevent FDA from issuing new ones after September 2026. FDA September 30 Deadline for submission of Advancing RWE Pilot Program projects A semi-annual deadline for FDA’s Advancing Real-World Evidence Program is set for the end of the fiscal year. and the E.C.

FDA 40

FDA Science Regulations Biosimilars 40

Agency IQ

JUNE 9, 2023

What will the orphan drug market exclusivity haircut mean for industry? Just over a month ago, the European Commission released its proposal for the new pharmaceutical directive and regulation. The average annual growth in non-orphan pharmaceutical expenditure in the same period was only 3%. member states.

Marketing 40

Marketing Regulations Biosimilars Drugs 40